$BCYC
Bicycle Therapeutics PLC

2023 Q2 Form 10-Q Financial Statement

#000155837023007979 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $11.40M $4.896M $3.860M
YoY Change 160.32% 26.84% 113.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.18M $14.04M $16.85M
YoY Change 36.2% -16.69% 107.98%
% of Gross Profit
Research & Development $39.72M $32.21M $14.28M
YoY Change 100.06% 125.5% 47.36%
% of Gross Profit
Depreciation & Amortization $1.645M $1.557M $422.0K
YoY Change 174.17% 268.96% 29.85%
% of Gross Profit
Operating Expenses $54.90M $46.70M $31.24M
YoY Change 73.3% 49.47% 75.21%
Operating Profit -$43.11M -$41.80M -$27.38M
YoY Change 57.92% 52.66% 70.89%
Interest Expense $381.0K $808.0K $818.0K
YoY Change -56.85% -1.22% 56.7%
% of Operating Profit
Other Income/Expense, Net -$9.000K $2.121M -$600.0K
YoY Change -136.0% -453.5% 18.34%
Pretax Income -$43.12M -$39.68M -$27.98M
YoY Change 58.09% 41.81% 69.28%
Income Tax -$517.0K -$600.0K -$400.0K
% Of Pretax Income
Net Earnings -$42.60M -$39.10M -$27.56M
YoY Change 58.97% 41.85% 70.24%
Net Earnings / Revenue -373.81% -798.61% -714.09%
Basic Earnings Per Share -$1.41 -$1.30 -$0.93
Diluted Earnings Per Share -$1.41 -$1.30 -$0.93
COMMON SHARES
Basic Shares Outstanding 30.04M 30.02M 29.61M
Diluted Shares Outstanding 30.19M 30.00M 29.61M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $340.4M $293.8M $407.4M
YoY Change -8.67% -27.88% 107.95%
Cash & Equivalents $340.4M $293.8M $407.4M
Short-Term Investments
Other Short-Term Assets $10.02M $10.93M $9.067M
YoY Change 6.02% 20.5% 51.12%
Inventory
Prepaid Expenses
Receivables $45.09M $50.00M $0.00
Other Receivables $12.88M $26.51M $13.33M
Total Short-Term Assets $408.4M $381.3M $429.8M
YoY Change -0.02% -11.29% 99.52%
LONG-TERM ASSETS
Property, Plant & Equipment $33.59M $18.26M $8.849M
YoY Change 99.79% 106.36% 40.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.15M $10.57M $4.198M
YoY Change 138.25% 151.69% 90.82%
Total Long-Term Assets $45.74M $47.55M $29.80M
YoY Change 23.66% 59.57% 254.73%
TOTAL ASSETS
Total Short-Term Assets $408.4M $381.3M $429.8M
Total Long-Term Assets $45.74M $47.55M $29.80M
Total Assets $454.2M $428.8M $459.6M
YoY Change 1.95% -6.69% 105.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.250M $2.813M $3.999M
YoY Change 8.05% -29.66% 299.9%
Accrued Expenses $34.35M $25.21M $12.27M
YoY Change 102.64% 105.56% 27.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.27M $53.00M $35.41M
YoY Change 74.8% 49.64% 70.26%
LONG-TERM LIABILITIES
Long-Term Debt $30.51M $30.42M $30.01M
YoY Change 1.22% 1.36% 1.72%
Other Long-Term Liabilities $131.3M $4.081M $3.362M
YoY Change 3927.42% 21.39% -89.29%
Total Long-Term Liabilities $161.8M $34.50M $33.37M
YoY Change 384.39% 3.38% -45.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.27M $53.00M $35.41M
Total Long-Term Liabilities $161.8M $34.50M $33.37M
Total Liabilities $234.1M $185.6M $129.3M
YoY Change 74.56% 43.57% 58.07%
SHAREHOLDERS EQUITY
Retained Earnings -$412.8M -$370.2M -$245.9M
YoY Change 51.32% 50.55%
Common Stock $396.0K $389.0K $385.0K
YoY Change 2.86% 1.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $220.1M $243.2M $330.3M
YoY Change
Total Liabilities & Shareholders Equity $454.2M $428.8M $459.6M
YoY Change 1.95% -6.69% 105.35%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$42.60M -$39.10M -$27.56M
YoY Change 58.97% 41.85% 70.24%
Depreciation, Depletion And Amortization $1.645M $1.557M $422.0K
YoY Change 174.17% 268.96% 29.85%
Cash From Operating Activities $34.10M -$46.41M -$26.40M
YoY Change -244.9% 75.8% 92.6%
INVESTING ACTIVITIES
Capital Expenditures $277.0K $2.099M $4.756M
YoY Change -102.83% -55.87% 663.4%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$277.0K -$2.099M -$4.756M
YoY Change -97.17% -55.87% 663.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.29M 2.718M 450.0K
YoY Change 6203.59% 504.0% -99.39%
NET CHANGE
Cash From Operating Activities 34.10M -46.41M -26.40M
Cash From Investing Activities -277.0K -2.099M -4.756M
Cash From Financing Activities 12.29M 2.718M 450.0K
Net Change In Cash 46.11M -45.34M -31.31M
YoY Change -239.16% 44.81% -152.26%
FREE CASH FLOW
Cash From Operating Activities $34.10M -$46.41M -$26.40M
Capital Expenditures $277.0K $2.099M $4.756M
Free Cash Flow $33.82M -$48.51M -$31.16M
YoY Change -346.28% 55.7% 117.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3860000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9042000
CY2022Q1 bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
375000
CY2023Q1 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
4896000
CY2022Q1 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
3860000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001761612
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30001725
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29605143
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29873893
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30031758
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10926000
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
0
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2023Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
0
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38916
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Blocks A & B, Portway Building, Granta Park
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Great Abington, Cambridge,
CY2023Q1 dei Entity Address Country
EntityAddressCountry
GB
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB21 6GS
CY2023Q1 dei City Area Code
CityAreaCode
+44
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
1223 261503
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-27564000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9022000
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4896000
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30043486
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293815000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
339154000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
50000000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2045000
CY2023Q1 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
26512000
CY2022Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
19162000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
381253000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
369383000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18261000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19110000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18721000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13658000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10566000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8458000
CY2023Q1 us-gaap Assets
Assets
428801000
CY2022Q4 us-gaap Assets
Assets
410609000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2813000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6472000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25212000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26452000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24970000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20418000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
52995000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53342000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30417000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30315000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14394000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10885000
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
83751000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41455000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4081000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3829000
CY2023Q1 us-gaap Liabilities
Liabilities
185638000
CY2022Q4 us-gaap Liabilities
Liabilities
139826000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30031758
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29873893
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
389000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
387000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
612863000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
601105000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
71000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
387000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-370160000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331096000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243163000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270783000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
428801000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
410609000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32211000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14284000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14488000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16959000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
46699000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
31243000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-41803000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27383000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
2929000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
218000
CY2023Q1 us-gaap Interest Expense
InterestExpense
808000
CY2022Q1 us-gaap Interest Expense
InterestExpense
818000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2121000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-600000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39682000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27983000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-618000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-419000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39064000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30001725
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30001725
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29605143
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39064000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-316000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39380000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26644000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270783000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2716000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9042000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-316000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39064000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243163000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10198000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-39064000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10198000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1557000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
422000
CY2023Q1 bcyc Non Cash Interest Expense
NonCashInterestExpense
102000
CY2022Q1 bcyc Non Cash Interest Expense
NonCashInterestExpense
135000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2106000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-748000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2519000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-991000
CY2023Q1 bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
6830000
CY2022Q1 bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
2774000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1735000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1341000
CY2023Q1 bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1009000
CY2022Q1 bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-650000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2001000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-255000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3130000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2337000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1034000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-105000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4900000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3850000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
160000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
178000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46411000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26400000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2099000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4756000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2099000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4756000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2716000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
450000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2718000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
450000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
453000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-603000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45339000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31309000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
339154000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
438680000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293815000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
407371000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
679000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
664000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-35000
CY2023Q1 bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1351000
CY2023Q1 bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
-1737000
CY2022Q1 bcyc Increase Decrease Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
1630000
CY2023Q1 bcyc Advance Billings On Deferred Revenue Included In Accounts Receivable
AdvanceBillingsOnDeferredRevenueIncludedInAccountsReceivable
50000000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5849000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3120000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293800000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39100000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27600000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-370200000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue recognition, share-based compensation expense, valuation of right-of-use assets and liabilities, and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
256100000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
276100000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27021000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26973000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8760000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7863000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18261000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19110000
CY2023Q1 us-gaap Depreciation
Depreciation
1600000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2023Q1 bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4380000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9928000
CY2023Q1 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
11646000
CY2022Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
10859000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1436000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1068000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4655000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3125000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2459000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
970000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
636000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
502000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25212000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26452000
CY2023Q1 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2023Q1 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2023Q1 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2023Q1 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
752000
CY2022Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
682000
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
335000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
367000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
30417000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
30315000
CY2023Q1 bcyc Period Of Royalty Payments Agreed Under Arrangement
PeriodOfRoyaltyPaymentsAgreedUnderArrangement
P10Y
CY2023Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
32768000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
31500000
CY2023Q1 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
CY2023Q1 bcyc Number Of Voter Per Share
NumberOfVoterPerShare
1
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
59612613
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9042000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10198000
CY2023Q1 us-gaap Noncurrent Assets
NoncurrentAssets
36982000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4896000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3860000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
61873000
CY2023Q1 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
50000000
CY2023Q1 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
4896000
CY2023Q1 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
-1744000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
108721000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
12099000
CY2022 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
14463000
CY2022 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
7103000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
61873000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q1 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
4896000
CY2022Q1 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3819000
CY2022Q1 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
41000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1326000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
906000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
648000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
267000
CY2023Q1 us-gaap Lease Cost
LeaseCost
1974000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1173000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0762
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0704
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4323000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6279000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6366000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3876000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
821000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2616000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19049000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4655000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14394000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39064000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27564000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30001725
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29605143
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7750206
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5567066
CY2023Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2

Files In Submission

Name View Source Status
bcyc-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-23-007979-index-headers.html Edgar Link pending
0001558370-23-007979-index.html Edgar Link pending
0001558370-23-007979.txt Edgar Link pending
0001558370-23-007979-xbrl.zip Edgar Link pending
bcyc-20230331.xsd Edgar Link pending
bcyc-20230331x10q.htm Edgar Link pending
bcyc-20230331xex10d1.htm Edgar Link pending
bcyc-20230331xex10d2.htm Edgar Link pending
bcyc-20230331xex10d2002.jpg Edgar Link pending
bcyc-20230331x10q_htm.xml Edgar Link completed
bcyc-20230331xex10d3.htm Edgar Link pending
bcyc-20230331xex10d3002.jpg Edgar Link pending
bcyc-20230331xex10d4.htm Edgar Link pending
bcyc-20230331xex10d4002.jpg Edgar Link pending
bcyc-20230331xex10d5.htm Edgar Link pending
bcyc-20230331xex10d5002.jpg Edgar Link pending
bcyc-20230331xex10d6.htm Edgar Link pending
bcyc-20230331xex10d6002.jpg Edgar Link pending
bcyc-20230331xex10d7.htm Edgar Link pending
bcyc-20230331xex10d7002.jpg Edgar Link pending
bcyc-20230331xex10d8.htm Edgar Link pending
bcyc-20230331xex10d8002.jpg Edgar Link pending
bcyc-20230331xex31d1.htm Edgar Link pending
bcyc-20230331xex31d2.htm Edgar Link pending
bcyc-20230331xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
bcyc-20230331_def.xml Edgar Link unprocessable
bcyc-20230331_pre.xml Edgar Link unprocessable
bcyc-20230331_lab.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending